Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer

Breast Cancer Research

Table 1 Characteristics of patients with ipsilateral multifocal primary breast cancer

No. of patients (n)	180
No. of specimens (n)	183
Age, years (median, IQR)	60 (52–71)
Surgery, breast
Mastectomy	131 (71.6)
Breast-conserving surgery	52 (28.4)
Surgery, axilla
SLNB only	128 (70.0)
SLNB + ALND^a	25 (13.7)
ALND upfront	21 (11.5)
No axillary surgery performed	9 (4.9)
No. of primary tumors found in the breast specimen
2	141 (77.0)
3^b	27 (14.8)
4^c	12 (6.6)
5^d	3 (1.6)
No. of tumors assessed with IHC
2	166 (90.7)
3	16 (8.7)
4	1 (0.5)
Size of the largest tumor, mm
pT1	77 (42.1)
pT2	100 (54.6)
pT3	6 (3.3)
Nodal status
pN0	106 (57.9)
pN1	40 (21.9)
pN2	10 (5.4)
pN3	5 (2.7)
pN_micro	8 (4.4)
pN_ITC	5 (2.7)
No axillary surgery performed	9 (4.9)
Adjuvant therapy received
Endocrine therapy	168 (93.3)
Chemotherapy	64 (35.0)
Trastuzumab	21 (11.7)
Radiotherapy	93 (51.7)

Data are presented as number of specimens (%), except for age and adjuvant therapy received where data are presented as number of patients (%)
IQR interquartile range, SLNB Sentinel lymph node biopsy, ALND Axillary lymph node dissection, IHC immunohistochemistry
^aSentinel lymph node biopsy was performed during primary surgery with additional axillary lymph node dissection at a later occasion
^bOf the specimens with three primary tumors in the breast, 15 had immunohistochemistry (IHC) assessed on two tumors and 12 had IHC assessed on three tumors
^cOf the specimens with four primary tumors in the breast, nine had IHC assessed on two tumors and three had IHC assessed on three tumors
^dOf the specimens with five primary tumors in the breast, one had IHC assessed in two tumors, one had IHC assessed in three tumors, and one had IHC assessed in four tumors

ISSN: 1465-542X